Research, development, production and distribution of nutritional health supplements,
dermocosmetics, dietary foods for special medical purposes and medical devices
<a href="/events">We will be present </a>
<a href="/about-us/quality">Certified quality</a>

Amnol is committed to maintaining the quality of its products and manufacturing processes, ISO 9001 and ISO 22716 (GMP for cosmetic products) certifications, and by the compliance with the FDA code CFR 21 (GMP for food supplements). The company guarantees excellence in its nutritional health supplements, dermocosmetics and medical devices by means of scrupulous methods of control and state of the art instruments, thus safeguarding the well-being of end users.

<a href="/expert">Ask the expert</a>

Our experts are at your disposal for any enquiries you may have regarding Amnol's products and will respond to your requests for any further information or informative literature. Please contact them by email or call on our toll free number.

News from the world

News from the world

  • Preliminary report of a new type of braided vein s...
    Conclusion The novel stent significantly increases the radial resistive force and does not increase vascular injury, thrombus and ...
  • A practical approach to tumescent local anaesthesi...
    Conclusion This report of over 1000 endovenous procedures demonstrates safe performance of laser and radiofrequency treatments usi...
  • Need for adjunctive procedures following cyanoacry...
    Conclusions Closure rates were high in the absence of the use of compression stockings or side branch treatment. Improvement in qu...
  • CCSVI, Chlamydia pneumoniae and multiple sclerosis...
    Authors: Thibault P PMID: 30217137 [PubMed - as supplied by publisher] (Source: Phlebology)
  • ClosureFast endovenous radiofrequency ablation for...
    Conclusion Disease progression was twice as high as the recanalization rate at three years post-treatment using ERFA in this study...
  • Chronic cerebrospinal venous insufficiency, chlamy...
    Authors: Lewis A PMID: 30200825 [PubMed - as supplied by publisher] (Source: Phlebology)
  • Compliance with compression therapy in primary chr...
    Conclusions Compliance with compression therapy in chronic venous disease is still a subject of concern as most patients are not u...
  • The ATTRACT trial may seem more attractive than it...
    Authors: Aherne TM, Walsh SR, O'Sullivan GJ, Davies AH, Tang TY PMID: 30157722 [PubMed - as supplied by publisher] (Source: Ph...
  • Impact of copper compression stockings on venous i...
    Conclusion This study demonstrates the beneficial effect of copper on lipodermatosclerosis secondary to chronic venous disease wit...
  • Comparison of cyanoacrylate embolization and radio...
    Conclusion Cyanoacrylate embolization offers equivalent success rates with lower mid-term complication rates as radiofrequency abl...
Newsletter

Newsletter

Sign up to our newsletter to keep up-to-date about what's new at AMNOL.








AMNOL Chimica Biologica S.r.l.
Registered office, Administrative and Sales Offices: Corso della Vittoria 14, 28100 Novara
Tel: +39 0321 499199 - Email: info@amnol.net
Share Capital € 250,000 issued capital R.E.A. Novara 10937 VAT code 01228730030 Tax Code 04170400156



AMNOL Chimica Biologica and Euronational are companies of the WTB group (company subject to management and co-ordination activity pursuant to Art.2497 CC by WTB Holding S.p.A. - Milan)


Quality Management System ISO 9001, GMP COSMETICS ISO 22716 and compliance with GMP FOOD SUPPLEMENTS (FDA CFR 21-part 111) issued by Bureau Veritas Italia SpA

Copyright 2018 by Amnol Chimica Biologica